Stockwinners Market Radar for February 23, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

17:50 EST Deckers Outdoor director Shanahan sells 3,672 common shares - In a regulatory filing, Deckers Outdoor director Lauri Shanahan disclosed the sale of 3,672 common shares of the company on February 6 at a price of $832.22 per share.

17:20 EST General Dynamics awarded $150.98M Navy contract action modification - General Dynamics was awarded a not-to-exceed $150.98M undefinitized contract action modification to previously awarded contract for long lead time material associated with the Virginia Class submarines SSN 814, SSN 815, SSN 816, and SSN 817. Work is expected to be completed by September 2035. FY24 shipbuilding and conversion funding in the amount of $150,984,000 will be obligated at time of award and will not expire at the end of the current fiscal year. The statutory authority for this sole source award is in accordance with Federal Acquisition Regulation 6.302-1 - Only one responsible source and no other supplies or services will satisfy agency requirements. Naval Sea Systems Command, Washington, D.C., is the contracting activity.

16:30 EST MoneyHero names Rohith Murthy CEO - MoneyHero announced the appointment of Rohith Murthy as its new Chief Executive Officer, effective immediately. Prior to his appointment to CEO, Mr. Murthy served as MoneyHero's Chief Business Officer, a role he assumed earlier this year following consistent promotions over the course of his nearly ten-year tenure with the Company. "On behalf of the Board, I want to congratulate Rohith, who is the right person to lead the Company forward, on this well-deserved appointment," said Kenneth Chan, Board Chair and Director with MoneyHero. "Rohith's deep understanding of digital finance, his proven leadership and longstanding track record with the Company, and his vision for using technology to improve our platform make him the ideal leader to guide us through the next phase of growth and innovation."

16:18 EST Zions Bancorp announces executive leadership changes - Zions Bancorporation announced several leadership changes which will become effective on April 1, at Zions Bank, Zions Bancorporation's largest banking division, and at the parent company: A. Scott Anderson, who has served as president and CEO of Zions Bank since 1998, will retire from his managerial duties following a 33-year career with the bank. Scott will become non-executive chairman of Zions Bank. Paul E. Burdiss, who has served as Zions Bancorporation's executive vice president and chief financial officer since 2015, will succeed Mr. Anderson as president and CEO of Zions Bank. R. Ryan Richards will become executive vice president and chief financial officer of Zions Bancorporation, having served as the company's corporate controller for the past two years. Thomas E. Laursen, Zions Bancorporation's general counsel, will retire and be succeeded by Rena Miller, who is currently the company's deputy general counsel.

16:13 EST Vertex Pharmaceuticals CSO Altshuler sells 3,002 common shares - In a regulatory filing, Vertex Pharmaceuticals CSO David Altshuler disclosed the sale of 3,002 common shares of the company on February 21 at a price of $421.77 per share.

16:12 EST Cognizant director Patsalos-Fox sells 10,000 class A shares - In a regulatory filing, Cognizant director Michael Patsalos-Fox disclosed the sale of 10,000 class A common shares of the company on February 21 at a price of $76.7323 per share.

16:09 EST Mesa Air receives noncompliance notice from Nasdaq - Mesa Air announced that it received a notice on February 21 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the company is not in compliance with Nasdaq Listing Rule 5250 because the company failed to timely file its quarterly report on Form 10-Q for the period ended December 31, 2023 with the Securities and Exchange Commission.

15:46 EST Undavia discloses 5.74% stake in GrafTech, proposes two candidates for board - In a regulatory filing, Nilesh Undavia disclosed a 5.74% stake in GrafTech and stated: "In light of what appear to be multiple very serious errors made by the incumbent Board, Mr. Undavia concluded that the incumbent Board was likely to make an additional serious error in their choice of CEO. Such an error might be catastrophic for shareholders... Mr. Undavia's request for only one Board seat was rejected by the incumbent Board. The manner in which the incumbent Board did this suggests that the incumbent Board may be entrenching itself. It suggests that the incumbent Board may be less interested in serving shareholders and more interested in the Board's own high fees... This set of events has convinced Mr. Undavia that the problems of the incumbent Board are much deeper than Mr. Undavia originally thought. Mr. Undavia has therefore concluded that only the addition of two new members to the Board will suffice to guarantee that the Board selects an appropriate CEO... Mr. Undavia has officially requested that the incumbent Board allow the Reporting Persons to list two of his candidates on the Universal Proxy that will be distributed for the annual meeting of shareholders. Mr. Undavia believes that when shareholders are able to review the qualifications of the two candidates selected by Mr. Undavia, shareholders will conclude that Mr. Undavia's two candidates should be elected to the Board to increase the chances of a positive outcome for all shareholders."

15:28 EST Atlantic Union Bankshares announces regulatory approvals to complete merger - Atlantic Union Bankshares Corporation announced that it has received regulatory approval from the Board of Governors of the Federal Reserve System to complete the previously announced merger of American National Bankshares with and into Atlantic Union Bankshares in an all-stock transaction. The Federal Reserve approval follows approvals from the Virginia State Corporation Commission and the shareholders of American National. "We are pleased to have received all of the regulatory and shareholder approvals necessary to close the merger, and we plan to close the transaction on April 1, 2024, subject to the satisfaction of customary closing conditions," said John Asbury, President and CEO of Atlantic Union Bankshares.

13:28 EST AstraZeneca says benralizumab met primary endpoint of MANDARA trial - Results from the MANDARA Phase III trial for Fasenra, or benralizumab, in patients with EGPA were published in the New England Journal of Medicine, as the first head-to-head trial of biologics in patients with EGPA, and the first to demonstrate that more than half of patients achieved remission with eosinophil-targeting biologic therapies, AstraZeneca reported. These findings were also presented as a late-breaking poster at the American Academy of Allergy Asthma & Immunology, or AAAAI, Annual Meeting in Washington, DC, February 23-26. MANDARA compared benralizumab to mepolizumab in patients with EGPA receiving oral corticosteroids with or without stable immunosuppressive therapy. Patients were randomized to receive either a single 30 mg subcutaneous injection of benralizumab, or three separate 100 mg subcutaneous injections of mepolizumab, once every four weeks. Full results showed that benralizumab met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab. The primary endpoint of adjusted rate of remission was 59% for benralizumab-treated patients at weeks 36 and 48, compared with 56% for mepolizumab. Remission in EGPA is defined as Birmingham Vasculitis Activity Score=0 and OCS dose less than or equal to 4 mg/day. A higher proportion of Fasenra-treated patients were able to fully taper off OCS during weeks 48 through 52. Additionally, 86% of benralizumab patients vs. 74% in the comparator arm had at least a 50% reduction in OCS dose during weeks 48 through 52. Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said, "The results from this trial are an important step forward for the EGPA community, as this is the first trial to demonstrate that remission from EGPA with an eosinophil-targeting biologic is achievable for the majority of patients. This is a significant advancement and shows that benralizumab helped patients achieve remission and reduce chronic OCS usage, in a convenient, single, monthly subcutaneous injection, and could alleviate some of the impact of this debilitating disease."

13:01 EST Baker Hughes reports U.S. rig count up 5 to 626 rigs

12:55 EST Moderna announces completion of construction of manufacturing plant in Quebec - Moderna announced the completion of construction of its mRNA manufacturing facility in Laval, Quebec. The facility is expected to be ready to manufacture respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals and certifications, "ensuring all vaccines manufactured meet the strictest quality, safety and performance standards," the company stated.

12:20 EST e.l.f. Beauty will do $440M of retail sales at Target this FY, says CEO - Comments taken from Consumer Analyst Group of New York Conference.

12:00 EST Andretti Acquisition rises 18.6% - Andretti Acquisition is up 18.6%, or $1.49 to $9.50.

12:00 EST Sunnova Energy falls -11.9% - Sunnova Energy is down -11.9%, or -$1.02 to $7.55.

12:00 EST Gray Television falls -23.8% - Gray Television is down -23.8%, or -$1.90 to $6.05.

11:51 EST U.S. video game spending grew 15% y/y in January, says Circana - Circana analyst Mat Piscatella said that projected total market spending on video game hardware, content and accessories in the U.S. grew 15% in January compared to a year ago, reaching $5.1B. The analyst noted that January 2024 was a 5-week period, while January 2023 was a 4-week period. A 15% increase in total projected spending on video game content drove the market's overall gain. Growth in digital content spending across Console, PC and VR platforms, along with a 5% increase in mobile games spending led the way, according to Sensor Tower. "Palworld" was January's biggest new release story, ranking 1st in monthly active users on Steam in the US during January according to Circana's Player Engagement Tracker, while placing 3rd on Xbox platforms behind only "Fortnite" and "Call of Duty HQ." Epic's "Fortnite" once again led in monthly active users across both PlayStation 5 (SONY) and Xbox Series (MSFT) consoles, with "Call of Duty HQ" ranking 2nd across both platforms. January video game hardware spending fell 4% when compared to January 2023, to $378M. Growth in Xbox Series hardware dollar sales was unable to offset declines across other platforms. PlayStation 5 was the best-selling hardware platform of January 2024 in both units and dollars, with Switch (NTDOY) placing 2nd in unit sales and Xbox Series ranking at #2 in dollar sales. With 39 months in market, life-to-date unit sales of PlayStation 5 are now tracking 7% ahead of PlayStation 4's pace, and 68% above that of PlayStation 3. Spending on video game accessories increased 45% when compared to January 2023, to $246 million. Gamepad spending increased by over 50% year-on-year. The PlayStation 5 Dual Sense Edge was the best-selling video game accessory of January in dollar sales. PlayStation Portal was shifted from the Hardware category to Accessories with January data. PlayStation Portal ranked 5th among video game accessories in consumer spending during January. Investors in Epic include Tencent (TCEHY), KKR (KKR), Disney (DIS), and Sony. Other publicly traded companies in the video game space include Electronic Arts (EA), Take-Two (TTWO), Ubisoft (UBSFY), Sega (SGAMY), Capcom (CCOEY), and Bandai Namco (NCBDY). Reference Link

11:22 EST Sizzle Acquisition Corp trading resumes

11:09 EST Nokia meets final NTIA guidelines, says compliant products available by mid-2024 - Nokia announced that its fiber optic broadband network electronics and optical modules manufactured in the U.S. meet the final Buy America guidelines announced by the Department of Commerce. "As a Buy America-compliant vendor, Nokia is one of the few that can supply products and services to critical broadband infrastructure projects focused on closing the digital divide. By meeting the final NTIA guidelines, Nokia can fully support states expected to launch BEAD projects in 2024. Nokia's first U.S.-made products that meet Buy America standards can be delivered in June 2024. Nokia will self-certify each product in line with NTIA specifications expected to be issued to ensure listed vendors comply with the final guidelines. Available for order as individual products or as part of Nokia's network-in-a-box program, the BEAD-certified solutions provide states with the technology needed to build end-to-end fiber networks to support BEAD's goal of expanding broadband access to more communities," the company stated. Reference Link

11:02 EST X3 Holdings 'on the brink' of unveiling something in semiconductor sector - X3 Holdings announced via X, the platform formerly called Twitter, that it is "on the brink of unveiling something in the semiconductor sector. Keep an eye out for our upcoming update!" Reference Link

10:40 EST Tilray looks forward to exploring 'path opened by German government' - Tilray Brands announced that its medical cannabis division, Tilray Medical, "enthusiastically welcomes the opening of the German medical cannabis market and the positive paradigm shift in German drug policy." The company stated: "Today's landmark passage of the German Medical Cannabis Act represents a significant step forward and puts public health in the spotlight while providing patients with easier access to high-quality cannabis medicines produced in Germany. Tilray Medical looks forward to working with numerous partners to utilize the production capacity at Tilray's state of the art Neumunster site, which is one of only three cannabis cultivation facilities located in Germany, in order to ensure that patients have improved access to the highest quality cannabis medicines grown in Germany. As a leader in the field of medical cannabis research and production, Tilray Medical strongly believes that these developments will have a positive impact on the health and well-being of many patients in Germany. We look forward to exploring the path opened by the German government and all stakeholders in promoting improved access to medical cannabis, and the opportunity to optimize care for our patients." Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek added: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs. Facilitating access to the highest quality cannabis medicines through the new Medical Cannabis Act, produced in Germany, will help to improve patient care and provide patients with a wider range of treatment options."

10:24 EST Maravai LifeSciences trading halted, volatility trading pause

10:00 EST Acco Brands falls -17.3% - Acco Brands is down -17.3%, or -$1.11 to $5.31.

10:00 EST Universal Insurance rises 13.8% - Universal Insurance is up 13.8%, or $2.38 to $19.61.

10:00 EST Carvana rises 40.7% - Carvana is up 40.7%, or $21.34 to $73.75.

09:50 EST Vroom trading resumes

09:47 EST CS Disco falls -10.9% - CS Disco is down -10.9%, or -80c to $6.52.

09:47 EST Evolent Health rises 9.2% - Evolent Health is up 9.2%, or $2.73 to $32.50.

09:47 EST Carvana rises 35.1% - Carvana is up 35.1%, or $18.38 to $70.79.

09:45 EST Vroom trading halted, volatility trading pause

09:43 EST Focus Universal sells Ontario warehouse resulting in $2.6M capital gain - Focus Universal announced the sale of its Ontario warehouse facility. "Our company has sold the warehouse for $7.1M, which has resulted in a $2.6M capital gain. As we purchased our warehouse for $4.5M in 2018, we feel it is the proper time to realize our investment given the changing market dynamics moving forward. We feel like our prudent and successful investment has yielded a beneficial return for the continued development of our company, and we plan to use the cash and proceeds to promote our Ubiquitor and SEC financial reporting automation software," said Focus CEO Desheng Wang.

09:41 EST Lotus Technology begins trading after combination with L Catterton Asia - Lotus Technology, a luxury electric vehicle maker, and L Catterton Asia Acquisition (LCAA), a special purpose acquisition company, announced last night the completion of their previously announced business combination. The listed company following the combination is Lotus Technology and its American depositary shares are trading on the Nasdaq under the ticker symbol "LOT." Qingfeng Feng, CEO of Lotus Tech, said: "Becoming a U.S-listed company marks a significant milestone in Lotus Tech's advancement into a global sustainable luxury mobility provider under the brand's Vision80 strategy. I look forward to further collaboration with LCAA as our respected partners, joining us in contributing to a greener future for all through sustainable innovation.

09:39 EST Nvidia market cap eclipses $2T - Nvidia shares are up $36.34, or nearly 5%, to $821.72, pushing the chipmaker's market cap over $2 trillion.

09:34 EST Arisz Acquisition Corp trading halted, volatility trading pause

09:30 EST ModivCare trading halted, volatility trading pause

09:07 EST SEALSQ Corp. selected to secure VESTEL's next generation 'Plug & Charge' - SEALSQ announced that it has been selected by VESTEL, a major global electric appliances manufacturer, to secure their latest Electric Vehicle, EV, "Plug & Charge" Stations. "By acting as a single security provider across the chain of trust, SEALSQ is proud to support OEMs like VESTEL, who can achieve the latest level of security and regulation compliance while reducing deployment complexity and time-to-market" said Franck Buonanno, VP of Sales.

09:06 EST Vision Marine announces purchase order, distributorship agreement - Vision Marine Technologies announced partnership with Nautical Ventures Marine Group.This collaboration marks a significant milestone with an initial purchase order for 50 units of the Phantom, Vision Marine's innovative rotomolded, recyclable boat, and the establishment of an exclusive distributorship agreement for South Florida. Under the exclusive distributorship agreement, Nautical Ventures Marine Group will serve as the sole distributor of the Phantom in the vibrant and burgeoning South Florida market. This strategic partnership is expected to significantly enhance the visibility and availability of the Phantom, positioning it as a mainstay in the recreational marine landscape of Florida. Furthermore, the collaboration was showcased at the prestigious Miami Boat Show, where an additional four units of the Phantom were sold, with delivery anticipated in the coming months. This event not only highlighted the Phantom's appeal to a broad audience of boating enthusiasts but also underscored the industry's growing emphasis on sustainable marine solutions. The delivery of the 50 units of the Phantom will be spread over the next four months.

09:04 EST Entravision opens new news facility in Las Vegas - Entravision announced the opening of its new news facility in Las Vegas. This milestone underscores the Company's three decade commitment of empowering the Latino community through trusted news and resources.

09:04 EST Euronet appoints Sara Baack to board of directors - Euronet announced the appointment of Sara Baack to the Euronet Board of Directors effective February 20, 2024. Her appointment increases the size of the board from eight to nine members. Ms. Baack is a Founding Partner at Snowhawk LP, a private investment firm that targets strategic majority investments in businesses that power the economy's digital transition across cloud, connectivity and technology services sectors.

09:03 EST L3Harris Technologies increases quarterly cash dividend to $1.16 per share - The board of directors of L3Harris Technologies approved an increase in the company's per share quarterly cash dividend rate from $1.14 to $1.16 commencing with the dividend for the first quarter of the year, payable March 22 to shareholders of record as of the close of business on March 8. The dividend corresponds to an increase in the annualized rate from $4.56 to $4.64.

09:03 EST Greenbrook TMS announces delisting from Nasdaq - Greenbrook TMS announced receipt of the final delisting notice from the Listing Qualifications Department of the Nasdaq Stock Market due to the continued failure to satisfy either the $1.00 minimum bid price listing requirement in Nasdaq Listing Rule 5550(a)(2) or the minimum stockholders' equity requirements in Nasdaq Listing Rule 5550(b). Nasdaq has notified the company that trading of its common shares will be suspended as of the open of trading on February 26. After careful consideration, the company determined that it was in the overall best interests of the company not to appeal the decision. The company intends to quote the Common Shares on OTC Markets as soon as practicable following the suspension of its Common Shares on Nasdaq. Nasdaq has informed the company that it will file a Form 25-NSE with the U.S. SEC, which will remove the company's Common Shares from listing on Nasdaq and registration under Section 12(b) of the U.S. Securities Exchange Act of 1934.

08:44 EST Diana Shipping announces sale of m/v Houston for $23.3M - The Company announced that it has signed, through a separate wholly-owned subsidiary, a Memorandum of Agreement to sell to an unaffiliated third party, the 2009-built vessel "Houston", with delivery to the buyer latest by September 16, 2024, for a sale price of $23.3 million before commissions.

08:37 EST Jaguar Health receives hearing on Nasdaq listing compliance - Jaguar Health provided an update regarding the status of its listing with The Nasdaq Stock Market. "Jaguar requested a hearing to appeal a potential delisting of the Company's securities from Nasdaq, and I'm pleased to report that a hearing has been scheduled, " said Lisa Conte, Jaguar's president and CEO. "The Company's common stock will continue to trade on Nasdaq under the symbol 'JAGX' pending the ultimate decision of any appeal process, and Jaguar's board remains committed to taking all required steps to remain in compliance with Nasdaq's listing standards." As previously reported, on May 10, 2023 Jaguar was notified by Nasdaq's Listing Qualifications Staff that the bid price for the Company's common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing on Nasdaq. The Company was granted a grace period until May 6, 2024, to regain compliance. On February 15, 2024, the Company received a letter from the Staff indicating that as of February 14, 2024, the Company's common stock had a closing bid price of $0.10 or less for 10 consecutive trading days, subjecting the Company to the provisions of Nasdaq's "Low Priced Stocks Rule," and indicating Nasdaq's intention to delist the Company's securities from Nasdaq on February 26, 2024, unless the Company requests an appeal before the Nasdaq Hearings Panel.

08:34 EST Wintrust Financial, LPL Financial announce strategic relationship - LPL Financial Holdings (LPLA) and Wintrust Financial Corporation (WTFC) announced an agreement to transition support of the wealth management business of Wintrust Investments and certain private client business at Great Lakes Advisors, and their approximately 85 advisors and approximately $16 billion of brokerage and advisory assets to the LPL Institution Services platform. "At Wintrust, our focus on outstanding client service has served our customers well and has resulted in a formidable wealth management operation," said Tom Zidar, Chairman and Chief Executive Officer at Wintrust Wealth Management. "We believe LPL is the right partner to help us take our business to the next level. LPL's integrated advisor platform and ongoing investment in technology will enable our advisors and portfolio managers to do even more for our clients. We are excited about the strategic relationship with LPL and the growth opportunities ahead of us."

08:34 EST Biodexa announces results for Phase 1 study of MTX110, update for Tolimidone - Biodexa Pharmaceuticals announces an R&D update including positive top-line clinical trial results of a recently completed Phase 1 study of MTX110 in patients with diffuse midline glioma, or DMG, and results of a preclinical experiment designed to demonstrate tolimidone's potential for beta cell proliferation in an in vitro model. In an investigator initiated study conducted by Columbia University Irving Medical Center, patients newly diagnosed with DMG were administered MTX110 via convection enhanced delivery using a subcutaneous pump connected to a catheter directly implanted into the pons in a 3+3 dose-escalating design. As this was the first ever study of repeated infusions to the pons via an implanted CED catheter, the primary objective of the study was safety and tolerability and, accordingly, the number of infusions was limited to two, each of 48 hours, 7 days apart. Nine patients were treated in the study. One patient in the 60 M group suffered a severe adverse event assessed by the investigators as not related to the study drug but related to the infusion and tumor anatomy. Although the study was not powered to reliably demonstrate efficacy, median overall survival of patients in the study was 16.5 months. Tolimidone: On the Company's behalf, a CRO conducted an in vitro experiment designed to demonstrate tolimidone's potential for beta cell proliferation using reaggregated pancreatic islets. The results of the experiment were inconclusive in that they did not correlate with the results previously seen in in vitro and in vivo studies of tolimidone

08:32 EST Phunware to implement 1-for-50 reverse stock split - Phunware announced that on February 26, 2024, the Company will implement a 1-for-50 reverse stock split of its issued and outstanding common stock, par value $0.0001 per share. The reverse stock split will be effective as of 5 PM Eastern Time on February 26, 2024, and the Company's common stock will trade on a post-split adjusted basis as of the commencement of trading on February 27, 2024, under the existing trading symbol "PHUN." The CUSIP number for the Company's common stock following the reverse stock split will be 71948P 209.

08:18 EST Warner Bros. Discovery expects to continue to de-lever in 2024 - Says far healthier company, building momentum. Says "on track" to deliver 2025 EBITDA guidance. Comments taken from Q4 earnings conference call.

08:11 EST Ace Global Business Acquisition announces contribution to trust account - Ace Global Business Acquisition announced that Ace Global Investment Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $98,858.95 representing, approximately $0.05 per ordinary share, in order to extend the period of time the Company has to complete a business combination for an additional one month period, from March 9, 2024 to April 8, 2024. The Company issued a promissory note to the Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and is convertible into the Company's units at a price of $10.00 per unit at the closing of a business combination by the Company. The purpose of the extension is to provide time for the Company to complete a business combination.

08:09 EST United Airlines to launch daily nonstop flights between Guam and Tokyo-Haneda - United Airlines will launch daily nonstop flights between Guam and Tokyo Haneda International Airport on May 1. Flights will operate year-round and create a more direct link between Guam and Japan's capital, given the Haneda airport's proximity to the city center. These new flights build on United's 32 weekly flights between Guam and Tokyo-Narita, and tickets will go on sale Feb 23.

08:08 EST Blueprint Medicines announces PIONEER trial results - Blueprint Medicines announced PIONEER trial results highlighting the long-term efficacy and safety of AYVAKIT in patients with indolent systemic mastocytosis, as well as foundational preclinical data for BLU-808, an investigational highly selective and potent oral inhibitor of wild-type KIT. Blueprint Medicines will report a total of nine data presentations, including two oral presentations, reflecting the company's long-standing commitment to transform care for patients living with mast cell disorders. The datasets are being reported at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting being held February 23-26 in Washington, D.C. expectations for continued growth of Caplyta, upcoming data readouts in MDD, and progress of its pipeline in the medium/long term. "PIONEER data show that long-term treatment with AYVAKIT led to robust and durable clinical efficacy across a wide range of symptoms, and a well-tolerated safety profile that has remained remarkably consistent over time," said Becker Hewes, M.D., Chief Medical Officer at Blueprint Medicines. "These compelling long-term data, combined with the real-world experience of more than a thousand patients currently on therapy in the U.S., indicate our continued momentum in establishing AYVAKIT as a new standard of care for patients living with ISM. With an SM franchise anchored by AYVAKIT, and the opportunity to expand and extend our reach with elenestinib, Blueprint Medicines is transforming treatment across the spectrum of the disease and redefining what well-controlled means for patients."

08:06 EST 1847 Holdings announces $1.95M repayment of convertible notes - 1847 Holdings has paid off $1.95 million in debt, following its recent public offering.

08:05 EST Federal Agricultural Mortgage raises quarterly dividend 27% to $1.40 per share - This quarterly dividend, which represents an increase of 27% in Farmer Mac's quarterly dividend rate on a year-over-year basis, will be payable on March 28 to holders of record of common stock as of March 15.

08:02 EST Jasper Therapeutics presents data from preclinical briquilimab studies - Jasper Therapeutics is presenting results from three preclinical studies evaluating briquilimab, at the 2024 American Academy of Allergy, Asthma & Immunology, AAAAI, Annual Meeting, being held February 23-26 in Washington, D.C. One study will be featured in an oral presentation and two studies in poster presentations. Each of the studies being presented utilized Jasper's proprietary c-Kit Mouse, which was developed to enable direct testing of briquilimab across a number of disease models, overcoming the limitations of standard models which do not bind antibodies directed at the human c-Kit receptor. "We are excited to present promising preclinical results from multiple studies this year at AAAAI, which indicate that briquilimab may be able to mitigate the likelihood of severe allergic reaction and anaphylaxis," said Wendy Pang, M.D., Ph.D., Senior Vice President, Research and Translational Medicine. "Each of these studies was conducted using the Jasper c-Kit Mouse, which we believe enables the generation of preclinical data with superior clinical translatability, and in turn, informs our clinical development programs."

07:57 EST Criteo responds to letter from Petrus Advisers - Criteo issued the following statement in response to the recent letter made public by Petrus Advisers: "Criteo's Board and management team maintain a regular dialogue with our shareholders and value constructive input toward the shared goal of enhancing shareholder value. While we do not comment on discussions with specific shareholders, it is important to note that members of Criteo's management team and Board have held a number of discussions with Petrus Advisers over the past three years. We are carefully reviewing their letter and hope to continue to engage constructively with them. Our Board and management team are laser focused on executing Criteo's strategy and have a proven track record of taking decisive action to drive near- and long-term, sustainable value for shareholders: We are seeing strong results from our strategy to be the AdTech partner of choice for Commerce Media; Criteo achieved double-digit growth in 2023 for the second consecutive year. In 2023, we achieved the historic milestone of crossing $1 billion in Contribution ex-TAC for the first time in Criteo's history, with more than 50% coming from non-Retargeting solutions. We also achieved adjusted EBITDA of 30%, including over $70 million of annualized savings. We are increasing our leading market share in Retail Media, having surpassed $200 million in annual revenue. In Q4 of 2023, we delivered record top line with organic growth acceleration. We are disciplined in our approach to capital allocation to drive value, which includes returning capital to shareholders through share buybacks. Having completed over $125 million in share repurchases in 2023, the Board approved an additional $150 million to be added to our existing share repurchase authorization. As previously communicated, we have accelerated our share buyback in Q1 2024 under a new 10b5-1 plan. Our Board comprises eight highly qualified and diverse directors, seven of whom are independent, and we continuously review the composition of our Board to ensure alignment with our plan, including the appointment last year of Frederik van der Kooi, who brings extensive experience in building and scaling profitable global advertising businesses. We look forward to an ongoing dialogue with all shareholders as we continue to advance our value creation strategy."

07:49 EST Empire Petroleum sees Q4 production 185,000 barrels of oil equivalent - The company said, "Production and Expenses. The Company's Q4 2023 total production is estimated at 185,000 barrels of oil equivalent or approximately 2,011 barrels of oil equivalent per day (BOE/D) (approximately 64% oil), with estimated production revenue of approximately $9.9 million. Lease operating expenses including workovers trended higher than prior quarters and reflect a higher level of compliance-related activities. The Company's general and administrative expenses are expected to be higher on a sequential basis in Q4 2023 resulting from legal costs regarding financing and operations. The Company is continuing its closing process and analysis of its results including the finalization of proved oil and gas reserves and would note that the 12-month trailing average WTI price for 2023 is $78/barrel versus $94/barrel in 2022 and natural gas is $2.64 per MMBtu for 2023 versus $6.36 per MMBtu in 2022."

07:33 EST E.W. Scripps sees FY24 CapEx $70M-$80M

07:33 EST NLS Pharmaceutics submits plan to regain Nasdaq listing compliance - NLS Pharmaceutics has submitted the Company's plan, on time, to regain compliance with Nasdaq Listing Rule 5550(b)(1). On January 9, 2024, NLS received a letter from the Listing Qualifications staff of Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders' equity of at least $2,500,000. If the plan is approved, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter, or until July 8, 2024, to evidence compliance.

07:32 EST Brazilian delegation visits Aclara's heavy rare earths pilot plant - Aclara Resources announced that the Company hosted a delegation of representatives from the State of Goias, Brazil, in Concepcion, Chile, on February 15th. The purpose of the visit was to demonstrate the environmentally sustainable features of its patented technology, which has been implemented at the Company's pilot plant in Chile, and which will be used at the Carina Module project, located in Goias, Brazil. This visit followed Aclara's meeting with the authorities in Goias in on October 25th, 2023, when the Company's management presented the Carina Module project for the first time to the Governor and several other senior officials of the state of Goias. Aclara CEO, Ramon Barua, commented: "We extend our gratitude to the Brazilian authorities for this fruitful visit to our pilot plant in Chile. They had the opportunity to observe firsthand our environmentally responsible operations, witnessing the processing of the ionic clays sourced from our Carina Module project in Brazil. Our visitors share our commitment to sustainable mineral extraction and have conveyed their support for expediting the development of the Carina Module. Also, the Brazilian authorities visited our Aclara House in Penco, and witnessed firsthand how our Company interacts with the local community. Aclara remains fully committed to closely collaborating with the government of Goias to ensure the success of this project." Visit Highlights: Key government representatives from the State of Goias that took part in the visit included: The Secretary of Environment and Sustainable Development, Ms. Andrea Vulcanis, who will oversee the permitting process for the Carina Module; The Secretary of Industry, Trade and Services, Mr. Joel Santana, responsible for attracting investment in Goias; The State Deputy and President of the Chamber of Mines and Energy, Mr. Lineu Olimpio; President of the Goias State Extractive Industries Union, Mr. Luiz Vessani The Brazilian delegation took a guided tour of Aclara's pilot plant in Penco, Chile, where they learned how the Circular Mineral Harvesting process works. They saw firsthand that the clean process uses only recycled water, recirculating 95% of the water used back into the system and the low carbon footprint of the extraction method, as the ionic clays are processed without the need for grinding or milling. Our guests were also able to note that a tailings dam is not needed, and that 99% of the reagent used to separate the clays from the rare earths also is recycled back into the process. The delegation also visited one of Aclara's social engagement projects in Penco and held a meeting with local authorities, including the Governor of the Biobio region. Meetings with Company representatives included discussions regarding the global rare earths market, the Carina Module project, and opportunities for collaboration between Aclara and the government of Goias.

07:20 EST Vertex Pharmaceuticals reports CHMP opinion for label extension of Kalydeco - Vertex Pharmaceuticals announced that the European Medicines Agency's, or EMA's, Committee for Medicinal Products for Human Use, or CHMP, adopted an opinion for the label expansion of Kalydeco for the treatment of infants with cystic fibrosis, or CF, ages one month to less than four months old who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.

07:12 EST AerCap announces new $500M share repurchase program - "In February 2024, our Board of Directors approved a new share repurchase program authorizing total repurchases of up to $500 million of AerCap ordinary shares through September 30, 2024."

07:11 EST BioCryst presents real-world data on ORLADEYO - BioCryst Pharmaceuticals announced new analyses of real-world use of oral, once-daily ORLADEYO that showed patients who initiated ORLADEYO experienced rapid, substantial and sustained reductions in attack rates through 18 months of treatment regardless of the severity of their disease, their history of prior prophylaxis or their C1-inhibitor level and function. Presentations: Berotralstat Prophylaxis Reduces HAE Attack Rates Regardless of Baseline Attacks: Real-World Outcomes; Patients with C1-INH deficiency who received long-term prophylaxis with ORLADEYO achieved rapid reduction in patient-reported monthly HAE attack rates from baseline, regardless of the severity of their disease. Median attack rates decreased below baseline in the first 90 days of ORLADEYO treatment and remained below baseline across all additional 90-day intervals for up to 18 months. Additionally, when stratified by baseline attacks, median monthly attack rates decreased and remained below baseline for up to 540 days on ORLADEYO regardless of their attack rate at baseline. Consistently Low Hereditary Angioedema Attack Rates with Berotralstat Regardless of Prior Prophylaxis: Real-World Outcomes; Patients who initiated ORLADEYO and were previously on at least one other prophylactic therapy at some point during their lifetime also experienced rapid, substantial and sustained reductions in HAE attack rates regardless of prior prophylactic therapy, including lanadelumab, subcutaneous C1-INH and androgens. Of note, the median monthly attack rate for patients who were previously treated with lanadelumab decreased from 1.00 at baseline to 0.33 at Days 1-90 after initiating ORLADEYO and remained below baseline through Days 451-540. Real-World Effectiveness of Berotralstat in HAE With and Without C1-Inhibitor Deficiency; Similarly, a reduction in monthly HAE attack rates was observed in patients with HAE who have normal C1-INH level and function and those with C1-INH deficiency upon initiating ORLADEYO. Patients with normal C1-INH had a median attack rate at baseline of 3.00 attacks/month, which was reduced to 1.00 at Days 1-90 and remained below baseline through Days 451-540, while patients with C1-INH deficiency had a median attack rate at baseline of 1.33 attacks/month, which was reduced to and remained at 0.50 through Days 451-540.

07:09 EST Travere , CSL Vifor announce Sparsentan received positive CHMP opinion - Travere Therapeutics and CSL Vifor announced that the European Medicines Agency's, EMA, CHMP has recommended approval of sparsentan for the treatment of adults with primary IgA nephropathy with a urine protein excretion greater than1.0 g/day. IgAN is a rare kidney disease and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission's final decision regarding CMA for sparsentan. If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN. "The positive recommendation from the CHMP represents a significant advancement toward the delivery of new treatment options for people living with IgAN in Europe, who face the risk of progression to kidney failure and who currently have no approved non-immunosuppressive treatment options. The PROTECT Study is the only head-to-head study in IgAN against a maximally labeled dose of irbesartan, a current standard of care. The study demonstrated treatment with sparsentan resulted in a rapid and sustained reduction in proteinuria and has the potential to preserve kidney function and significantly delay time to kidney failure compared to an active comparator, suggesting long-term benefits in IgAN," said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. "Together with CSL Vifor, we look forward to the European Commission's decision in the second quarter of 2024."

07:08 EST Biogen's QALSODY received positive opinion from CHMP - Biogen announced the Committee for Medicinal Products for Human Use , CHMP, of the European Medicines Agency, EMA, adopted a positive opinion recommending a marketing authorization under exceptional circumstances for QALSODY for the treatment of adults with amyotrophic lateral sclerosis, ALS, associated with a mutation in the superoxide dismutase 1, SOD1, gene. If authorized by the European Commission, EC, QALSODY will be the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease.

07:05 EST Bristol Myers announces expiration of tender offer for RayzeBio - Bristol Myers Squibb (BMY) announced that its previously announced tender offer to acquire all of the outstanding shares of RayzeBio (RYZB) common stock for a purchase price of $62.50 per share in cash, or approximately $4.1B, expired at one minute after 11:59 p.m., Eastern Time, on February 22. Equiniti Trust Company, the depositary for the Offer, has advised that, as of the Expiration Time, approximately 53,052,499 shares of RazyeBio common stock were validly tendered and not validly withdrawn pursuant to the Offer, representing approximately 86% of the issued and outstanding shares of RayzeBio common stock at the Expiration Time. The parties expect the transaction to close on February 26, promptly following the acceptance of all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer.

06:58 EST Hyatt sees FY24 System-Wide RevPAR growth 3%-5% - Sees FY24 net rooms growth 5.5%-6%; CapEx ~$170M; FCF $625M-$675M.

06:46 EST Bloomin' Brands announces $350M share repurchase plan - "On February 13, our Board of Directors canceled $57.5 million of remaining authorization under our existing share repurchase program and approved a new $350.0 million authorization. The 2024 Share Repurchase Program includes capacity above our normal share repurchases activity to provide flexibility in retiring our convertible senior notes at or prior to their May 2025 maturity. The 2024 Share Repurchase Program will expire on August 13, 2025."

06:22 EST Intuitive Machines soars 40% to $11.56 after spacecraft lands on moon

06:19 EST Nextdoor reports preliminary Q4 WAU 41.8M - Reports WAU of 41.8M, an increase of 5% year-over-year and 3% quarter-over-quarter. Reports cash, cash equivalents, and marketable securities of $531M as of December 31, 2023.

06:07 EST NY AG James urges stricter warnings for Merck's Singulair - In a letter on Thursday, New York Attorney General Letitia James called on the FDA to "take immediate action" and renew alerts to doctors and patients about the dangerous effects of Singulair for children, saying that the current warnings about the drug's psychiatric side effects are not sufficient. James also called on the FDA to consider discouraging the prescription of Singulair to children. The FDA in 2020 warned that Merck's Singulair could cause aggression, agitation and even suicidal thoughts, but many people weren't informed, and the drug was still prescribed to 12M people in the U.S. as of 2022, The New York Times reported last month. Reference Link

06:03 EST Nextdoor board approves $150M increase to existing share repurchase plan - Nextdoor's Board of Directors has authorized a $150M increase to the company's existing share repurchase authorization (for a total authorization of $250M; approximately $77M of which has been executed to date) and extension of the program until March 31, 2026.

06:02 EST BrainStorm submits SPA request to FDA for study of NurOwn - BrainStorm announced that it has submitted as special protocol assessment, or SPA, request to the FDA for a Phase 3b study of NurOwn, its investigational treatment for amyotrophic lateral sclerosis, or ALS.

05:18 EST Flex LNG announce time charter for Flex Courageous extended by two years - Flex LNG has received notice that the charterer of Flex Courageous, a super major, has exercised its first extension option. Flex Courageous was fixed on a three-year time charter on November 1, 2021, together with Flex Resolute which was also recently extended by two years until 2027. The commencement of the time vharter for Flex Courageous was February 2022. Under the time charter, the charterer has the option to extend the period by two consecutive two year periods. Following this first option declaration, Flex Courageous will be firm until first quarter of 2027. The charterer will then have a final option to extend the time charter by another two years until 2029.

05:14 EST Travere Therapeutics, CSL Vifor get CHMP recommendation for sparsentan approval - CSL Vifor and Travere Therapeutics announced that the European Medicines Agency's, or EMA, CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion greater than1.0 g/day. IgAN is a rare kidney disorder and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission's final decision regarding CMA for sparsentan. If approved in Europe, sparsentan will be the first non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist for the treatment of IgAN.